Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -22.32 Million EUR | 31.95% |
| 2022 | -32.81 Million EUR | -64.02% |
| 2021 | -20 Million EUR | -8.42% |
| 2020 | -18.45 Million EUR | 13.62% |
| 2019 | -21.36 Million EUR | -366.14% |
| 2018 | 8.02 Million EUR | 124.87% |
| 2017 | -32.27 Million EUR | -28.04% |
| 2016 | -25.2 Million EUR | 45.64% |
| 2015 | -46.37 Million EUR | 4.49% |
| 2014 | -48.55 Million EUR | -13.3% |
| 2013 | -42.85 Million EUR | 0.8% |
| 2012 | -43.2 Million EUR | 0.97% |
| 2011 | -43.62 Million EUR | -27.49% |
| 2010 | -34.21 Million EUR | -25.13% |
| 2009 | -27.34 Million EUR | -51.93% |
| 2008 | -18 Million EUR | -226.03% |
| 2007 | -5.52 Million EUR | 74.94% |
| 2006 | -22.03 Million EUR | 0.0% |
| 2004 | -20.48 Million EUR | 1.87% |
| 2003 | -20.87 Million EUR | -13.41% |
| 2002 | -18.4 Million EUR | 16.13% |
| 2001 | -21.94 Million EUR | 2.37% |
| 2000 | -22.47 Million EUR | -23.35% |
| 1999 | -18.22 Million EUR | 47.93% |
| 1998 | -34.99 Million EUR | -195.12% |
| 1997 | -11.85 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -16.48 Million EUR | 0.0% |
| 2023 Q1 | -7.95 Million EUR | 54.63% |
| 2023 Q4 | -3.21 Million EUR | 0.0% |
| 2023 Q3 | -3.21 Million EUR | 79.79% |
| 2023 Q2 | -15.9 Million EUR | -100.0% |
| 2023 FY | -22.32 Million EUR | 31.95% |
| 2022 Q2 | -15.27 Million EUR | -100.0% |
| 2022 Q1 | -7.63 Million EUR | 1.25% |
| 2022 Q4 | -17.52 Million EUR | -100.0% |
| 2022 FY | -32.81 Million EUR | -64.02% |
| 2022 Q3 | -8.76 Million EUR | 42.65% |
| 2021 Q3 | -3.86 Million EUR | 67.22% |
| 2021 FY | -20 Million EUR | -8.42% |
| 2021 Q2 | -11.8 Million EUR | -100.0% |
| 2021 Q4 | -7.73 Million EUR | -100.0% |
| 2021 Q1 | -5.9 Million EUR | 60.71% |
| 2020 Q1 | -1.1 Million EUR | 68.02% |
| 2020 Q4 | -15.01 Million EUR | -100.0% |
| 2020 Q3 | -7.5 Million EUR | -239.14% |
| 2020 Q2 | -2.21 Million EUR | -100.0% |
| 2020 FY | -18.45 Million EUR | 13.62% |
| 2019 Q4 | -3.46 Million EUR | -100.0% |
| 2019 Q3 | -1.73 Million EUR | 88.72% |
| 2019 FY | -21.36 Million EUR | -366.14% |
| 2019 Q1 | -7.67 Million EUR | -166.99% |
| 2019 Q2 | -15.34 Million EUR | -100.0% |
| 2018 FY | 8.02 Million EUR | 124.87% |
| 2018 Q1 | -7.43 Million EUR | -6.78% |
| 2018 Q2 | -7.43 Million EUR | 0.0% |
| 2018 Q4 | 11.45 Million EUR | 0.0% |
| 2018 Q3 | 11.45 Million EUR | 253.98% |
| 2017 Q3 | -6.96 Million EUR | 24.08% |
| 2017 Q1 | -9.17 Million EUR | -46.25% |
| 2017 Q2 | -9.17 Million EUR | 0.0% |
| 2017 FY | -32.27 Million EUR | -28.04% |
| 2017 Q4 | -6.96 Million EUR | 0.0% |
| 2016 Q2 | -5.81 Million EUR | 0.0% |
| 2016 Q1 | -5.81 Million EUR | 28.38% |
| 2016 Q3 | -6.27 Million EUR | -7.78% |
| 2016 FY | -25.2 Million EUR | 45.64% |
| 2016 Q4 | -6.27 Million EUR | 0.0% |
| 2015 Q3 | -8.12 Million EUR | 24.97% |
| 2015 Q2 | -10.82 Million EUR | 0.0% |
| 2015 Q4 | -8.12 Million EUR | 0.0% |
| 2015 FY | -46.37 Million EUR | 4.49% |
| 2015 Q1 | -10.82 Million EUR | -8.39% |
| 2014 FY | -48.55 Million EUR | -13.3% |
| 2014 Q4 | -9.99 Million EUR | 0.0% |
| 2014 Q3 | -9.99 Million EUR | 5.44% |
| 2014 Q2 | -10.56 Million EUR | 0.0% |
| 2014 Q1 | -10.56 Million EUR | -7.32% |
| 2013 Q2 | -11.58 Million EUR | 0.0% |
| 2013 FY | -42.85 Million EUR | 0.8% |
| 2013 Q4 | -9.84 Million EUR | 0.0% |
| 2013 Q1 | -11.58 Million EUR | -8.06% |
| 2013 Q3 | -9.84 Million EUR | 15.0% |
| 2012 Q4 | -10.71 Million EUR | 0.0% |
| 2012 Q3 | -10.71 Million EUR | 0.0% |
| 2012 FY | -43.2 Million EUR | 0.97% |
| 2011 FY | -43.62 Million EUR | -27.49% |
| 2010 FY | -34.21 Million EUR | -25.13% |
| 2009 FY | -27.34 Million EUR | -51.93% |
| 2008 FY | -18 Million EUR | -226.03% |
| 2007 FY | -5.52 Million EUR | 74.94% |
| 2006 FY | -22.03 Million EUR | 0.0% |
| 2005 Q2 | -4.7 Million EUR | -7.35% |
| 2005 Q1 | -4.38 Million EUR | -6.9% |
| 2004 Q2 | -5.26 Million EUR | 2.86% |
| 2004 Q1 | -5.42 Million EUR | 17.77% |
| 2004 Q3 | -5.94 Million EUR | -12.78% |
| 2004 Q4 | -4.09 Million EUR | 31.05% |
| 2004 FY | -20.48 Million EUR | 1.87% |
| 2003 FY | -20.87 Million EUR | -13.41% |
| 2003 Q4 | -6.59 Million EUR | -50.86% |
| 2003 Q2 | -5.11 Million EUR | -6.98% |
| 2003 Q3 | -4.37 Million EUR | 14.59% |
| 2003 Q1 | -4.78 Million EUR | -3.52% |
| 2002 Q4 | -4.62 Million EUR | -9.85% |
| 2002 FY | -18.4 Million EUR | 16.13% |
| 2002 Q1 | -4.8 Million EUR | 25.78% |
| 2002 Q2 | -4.76 Million EUR | 0.78% |
| 2002 Q3 | -4.2 Million EUR | 11.67% |
| 2001 Q3 | -4.42 Million EUR | 20.06% |
| 2001 Q1 | -5.5 Million EUR | -22.62% |
| 2001 FY | -21.94 Million EUR | 2.37% |
| 2001 Q4 | -6.46 Million EUR | -46.28% |
| 2001 Q2 | -5.53 Million EUR | -0.49% |
| 2000 Q2 | -3.84 Million EUR | 41.14% |
| 2000 Q4 | -4.48 Million EUR | 40.86% |
| 2000 FY | -22.47 Million EUR | -23.35% |
| 2000 Q3 | -7.59 Million EUR | -97.62% |
| 2000 Q1 | -6.52 Million EUR | -19.69% |
| 1999 Q3 | -4.6 Million EUR | -0.95% |
| 1999 FY | -18.22 Million EUR | 47.93% |
| 1999 Q4 | -5.45 Million EUR | -18.54% |
| 1999 Q1 | -3.7 Million EUR | 21.97% |
| 1999 Q2 | -4.55 Million EUR | -23.01% |
| 1998 FY | -34.99 Million EUR | -195.12% |
| 1998 Q1 | -21.74 Million EUR | 0.0% |
| 1998 Q2 | -5.62 Million EUR | 74.11% |
| 1998 Q3 | -5.38 Million EUR | 4.37% |
| 1998 Q4 | -4.74 Million EUR | 11.8% |
| 1997 FY | -11.85 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -534.679% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 84.887% |
| Adocia SA | -21.16 Million EUR | -5.51% |
| Aelis Farma SA | -5.07 Million EUR | -339.701% |
| Biophytis S.A. | -17.02 Million EUR | -31.141% |
| Advicenne S.A. | -7.03 Million EUR | -217.565% |
| genOway Société anonyme | 1.56 Million EUR | 1524.366% |
| IntegraGen SA | -171.39 Thousand EUR | -12926.914% |
| Medesis Pharma S.A. | -3.95 Million EUR | -463.911% |
| Neovacs S.A. | -8.74 Million EUR | -155.368% |
| NFL Biosciences SA | -3.74 Million EUR | -496.133% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 28302.958% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -604.143% |
| Sensorion SA | -22.06 Million EUR | -1.199% |
| Theranexus Société Anonyme | -6.82 Million EUR | -227.009% |
| TME Pharma N.V. | -6.73 Million EUR | -231.473% |
| Valbiotis SA | -7.36 Million EUR | -203.04% |
| TheraVet SA | -1.57 Million EUR | -1321.525% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -9.752% |
| argenx SE | -272.91 Million EUR | 91.819% |
| BioSenic S.A. | -28.77 Million EUR | 22.413% |
| Celyad Oncology SA | -8.44 Million EUR | -164.299% |
| DBV Technologies S.A. | -67.26 Million EUR | 66.808% |
| Galapagos NV | 211.69 Million EUR | 110.547% |
| Genfit S.A. | -28.89 Million EUR | 22.724% |
| GeNeuro SA | -14.75 Million EUR | -51.304% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -45.176% |
| Innate Pharma S.A. | -7.57 Million EUR | -194.954% |
| Inventiva S.A. | -110.42 Million EUR | 79.78% |
| MaaT Pharma SA | -19.71 Million EUR | -13.242% |
| MedinCell S.A. | -25.03 Million EUR | 10.824% |
| Nanobiotix S.A. | -39.7 Million EUR | 43.758% |
| Onward Medical N.V. | -36.18 Million EUR | 38.288% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -565.922% |
| OSE Immunotherapeutics SA | -23 Million EUR | 2.934% |
| Oxurion NV | -18.96 Million EUR | -17.708% |
| Pharming Group N.V. | -9.75 Million EUR | -128.85% |
| Poxel S.A. | -35.09 Million EUR | 36.369% |
| GenSight Biologics S.A. | -26.22 Million EUR | 14.844% |
| Financière de Tubize SA | 88.15 Million EUR | 125.329% |
| UCB SA | 343 Million EUR | 106.51% |
| Valneva SE | -101.42 Million EUR | 77.987% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 21.219% |